Development of Nanobrite for Ultra High Definition MRI

Focus: 

To further develop a magnetic resonance imaging agent with significantly enhanced imaging ability

Anticipated Impact: 

Dramatically improved diagnosis of diseases characterized by reduced blood flow, and improved patient safety

Abstract: 

Magnetic resonance imaging (MRI), although safe, is not able to image blood vessels well, since image-enhancing contrast agents leak out of blood vessels quickly. Further development of "Nanobrite," a nanoparticle contrast agent previously funded by LSDF, will be conducted.  Nanobrite’s particle size keeps it from leaking out of blood vessels. Further, it may be safer for patients with inadequate kidney function, since Nanobrite is cleared from the body by a different mechanism. A standard suite of safety/toxicology/efficacy studies will be conducted to prepare for an IND submission to the FDA, at project end. Two indications that cannot be imaged well now, peripheral arterial disease and renal stenosis, will be evaluated. Matching funds will come from private investors, including an Asian pharmaceutical company.

Collaborating organizations: Averitas Imaging Technologies, Inc.; Benaroya Research Institute at Virginia Mason; Seattle Radiologists; University of Washington

Safer MRI Contrast Agent

Grant Update

Principal Investigator:
Rodney Ho
Grantee Organization:
Nova TheraNostics LLC
Grant Title:
Development of Nanobrite for Ultra High Definition MRI
Grant Cohort and Year:
2015 Matching (05)
Grant Period:
08/16/2015 - 08/15/2018 (Active)
Grant Amount:
$500,000

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Seattle

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Safer MRI Contrast Agent